Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
- 1LVR Hospital Essen Department of Addictive Behaviour and Addiction Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany
- 2Psychosomatische Klinik Bergisch Gladbach, Bergisch Gladbach, Germany
- 3LVR Clinic Viersen, Viersen, Germany
- 4Castrop-Rauxel Evangelical Hospital, Castrop-Rauxel, Germany
- 5LWL-Klinik Münster, Münster, North Rhine-Westphalia, Germany
- 6LVR Clinic Langenfeld, Langenfeld, Germany
- 7Alexianer Hospital, Krefeld, Germany
- 8Alexius/Josef Hospital, Neuss, Germany
- 9LVR Clinic Düren, Düren, Germany
A Corrigendum on
Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
by Specka, M., Kuhlmann, T., Sawazki, J., Bonnet, U., Steinert, R., Cybulska-Rycicki, M., et al. (2020). Front. Psychiatry 11:569. doi: 10.3389/fpsyt.2020.00569
In the published article, there was an error in affiliation 7 Instead of “Clinic Maria Hilf GmbH, Moenchengladbach, Germany” it should be “Alexianer Hospital, Krefeld, Germany.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: novel psychoactive substances, pregabalin abuse, multiple substance use, drug dependence, drug detoxification, opiate dependents
Citation: Specka M, Kuhlmann T, Sawazki J, Bonnet U, Steinert R, Cybulska-Rycicki M, Eich H, Zeiske B, Niedersteberg A, Schaaf L and Scherbaum N (2021) Corrigendum: Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment. Front. Psychiatry 12:681542. doi: 10.3389/fpsyt.2021.681542
Received: 16 March 2021; Accepted: 17 March 2021;
Published: 21 April 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Specka, Kuhlmann, Sawazki, Bonnet, Steinert, Cybulska-Rycicki, Eich, Zeiske, Niedersteberg, Schaaf and Scherbaum. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Michael Specka, bWljaGFlbC5zcGVja2EmI3gwMDA0MDt1bmktZHVlLmRl